Methicillin-resistant Staphylococcus aureus Therapeutics - Pipeline Assessment

Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 report is an essential source of information and analysis on the global Methicillin-Resistant Staphylococcus Aureus Therapeutics market. The report identifies the key trends shaping and driving the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products in the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics sector.

Scope

The report provides information on the key drivers and challenges of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market landscape? – Identify, understand and capitalize.

Companies Mentioned

Basilea Pharmaceutica Ltd. Durata Therapeutics, Inc. The Medicines Company Trius Therapeutics, Inc. AstraZeneca PLC GlaxoSmithKline plc Rib-X Pharmaceuticals, Inc. Wockhardt Limited

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84554/methicillin-resistant-staphylococcus-aureus-mrsa-therapeutics-pipeline-assessment-and-market-forecasts-to-2019.html